AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Vidyullatha Vasireddy(Penn Presbyterian Medical Center), Jean Bennett(Penn Presbyterian Medical Center)
Cited by 78
Related Papers
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate
|Nature Genetics|2000|506
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
|Science Translational Medicine|2012|390
Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA
|Molecular Therapy — Nucleic Acids|2018|28